Skip to main content
Clinical Trials/NCT04948840
NCT04948840RecruitingNot Applicable

Pilot Study of the Predictive Value of TREM1 Expression and Activation in Inflammation and Radio-induced Mammary Fibrosis

Centre Francois Baclesse, Luxembourg3 sites in 2 countries20 target enrollmentStarted: April 1, 2022Last updated:
Conditions

Trial Snapshot

Phase
Not Applicable
Status
Recruiting
Sponsor
Enrollment
20
Locations
3
Primary Endpoint
Coorelate the amount of circulating TREM1 with the presence or absence of early persistent radiation-induced epidermis.

Study Overview

Brief Summary

Breast cancer is the most common cancer in the world. Half of patients with such cancer are treated with radiation therapy. Some patients will develop cutaneous or subcutaneous fibrosis, more or less bothersome. Several studies have shown a correlation between an inflammatory reaction and a protein, called TREM-1. But to date, no link has been proven between TREM-1 and inflammation / fibrosis in the phenomena of fibrosis induced by radiotherapy in patients with breast cancer. Our study aims to understand the involvement of this TREM-1 protein in the development of fibrosis or radio-epidermis in patients with breast cancer.

Study Design

Study Type
Interventional
Allocation
Non Randomized
Intervention Model
Parallel
Primary Purpose
Other
Masking
None

Eligibility Criteria

Ages
18 Years to — (Adult, Older Adult)
Sex
Female
Accepts Healthy Volunteers
No

Inclusion Criteria

  • for groups A, B, C, D:
  • Systemic inflammatory disease associated with individual radiosensitivity
  • Dermatological pathology in the breast
  • Radiotherapy having delivered an overdose> 107% of the prescribed dose in at least 10% of the PTV
  • Active smoking
  • Chronic systemic anti-inflammatory therapy, immunotherapy, immunosuppressants, anti-TNF

Exclusion Criteria

  • Not provided

Outcomes

Primary Outcomes

Coorelate the amount of circulating TREM1 with the presence or absence of early persistent radiation-induced epidermis.

Time Frame: after recruitment of all samples, an average of 2 years

Correlate the amount of circulating TREM1 with the presence or absence of early persistent radiation-induced epidermis.

Secondary Outcomes

  • Intrinsic characteristics of the TREM1 blood assay in ELISA technique(after recruitment of all samples, an average of 2 years)
  • Correlate the amount of circulating TREM1 with the presence or absence of late radio-induced fibrosis / atrophy(after recruitment of all samples, an average of 2 years)
  • correlate TREM-1 expression with circulating markers of inflammation such as IL-6, CRP, and fibrosis such as TGF-beta, IL-1beta, TNF-alpha(after recruitment of all samples, an average of 2 years)

Investigators

Sponsor
Centre Francois Baclesse, Luxembourg
Sponsor Class
Other
Responsible Party
Sponsor

Study Sites (3)

Loading locations...

Similar Trials